Corona Remedies IPO
GMP, Subscription, Price, Dates & Financial Details
Healthcare Services
Corona Remedies Limited, incorporated in August 2004, is a fast-growing pharmaceutical formulation company focused on the Indian market. The company develops, manufactures, and markets a wide range of branded products across women’s healthcare, cardio-diabeto, pain management, urology, and other…
Open Date
Mon, 08 Dec 2025
Close Date
Wed, 10 Dec 2025
Price Band
₹ 1008 – 1062
Lot Size
14
Issue Size
₹ 655.37 Cr
Minimum Investment
₹ 14,868 (14 Shares)
Grey Market Premium Analysis
Day Wise GMP→Unofficial premium quoted in the grey market, tracked daily against the price band cap.
Grey market trading is unregulated. GMP figures are indicative only and should not be the sole basis for investment decisions - treat as a sentiment indicator, not a guarantee.
IPO Details
Corona Remedies IPO has successfully completed its IPO process and is now listed on the NSE and BSE. According to the Red Herring Prospectus (RHP), the IPO was a book-built issue with a total issue size of ₹655.37 Crore and an offer for sale (OFS) of 61.71 Lakh equity shares aggregating to ₹655.37 Crore by the existing shareholders.
The Corona Remedies IPO remained open for subscription from December 08, 2025, to December 10, 2025. The basis of allotment was finalized on December 11, 2025, and the company's shares were listed on the NSE and BSE on December 15, 2025.
The company had fixed the price band at ₹1008 to ₹1062 per share, with a lot size of 14 shares. Retail investors were required to make a minimum investment of ₹14,868 (based on the upper price band) to apply for one lot.
The IPO also included a reservation of 61,320 equity shares for eligible employees, who received a discount of ₹54 per share.
Bigshare Services Pvt Ltd served as the registrar to the issue. IIFL Capital Services Limited, JM Financial Limited, and Kotak Mahindra Capital Company Limited acted as the Book Running Lead Managers (BRLMs) to the issue.
With the successful completion of the IPO process, Corona Remedies Limited is now a publicly listed company on the NSE and BSE. Investors can track the company's share price, trading performance, financial results, and corporate announcements through the stock exchanges.
Corona Remedies IPO Timeline (Tentative)
- IPO Open Date
- Mon, 08 Dec 25
- IPO Close Date
- Wed, 10 Dec 25
- Basis of Allotment
- Thu, 11 Dec 25
- Initiation of Refunds
- Fri, 12 Dec 25
- Credit of Shares to Demat
- Fri, 12 Dec 25
- Listing Date
- Mon, 15 Dec 25 — NSE & BSE
Open Date
08 December 2025
Close Date
10 December 2025
Basis Of Allotment
11 December 2025
Listing Date
15 December 2025
IPO Subscription
Check Live Subscription →The Corona Remedies IPO has received bids for 62,65,41,440 shares against 45,71,882 shares offered, resulting in an overall subscription of 137.04x. the NII category is subscribed 208.88x, Retail Investors 28.73x, Employees 14.72x, and QIBs 278.52x. Within the NII category, BNII is subscribed 234.02x, while SNII is subscribed 158.62x.
QIB
278.52x
NII
208.88x
BNII
234.02x
SNII
158.62x
RII
28.73x
EMP
14.72x
Total
137.04x
IPO Reservations
The Retail Individual Investor (RII) category has the highest allocation with 22,55,281 shares, representing 49.33% of the total issue. Qualified Institutional Buyers (QIBs) are allocated 12,88,732 shares (28.19%), while Non-Institutional Investors (NIIs) receive 9,66,549 shares (21.14%).
| Category | Shares Offered | Shares Offered % |
|---|---|---|
| Qualified Institutions | 1,288,732 | 28.19% |
| Non-Institutional | 966,549 | 21.14% |
| BNII | 644,366 | 14.09% |
| SNII | 322,183 | 7.05% |
| Retail Investors | 2,255,281 | 49.33% |
| Employees | 61,320 | 1.34% |
| Total | 4,571,882 | 100% |
Financials Details(₹ in Crores)
| Particular | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 1012.38 | 929.86 | 830.58 | 595.02 |
| Revenue | 348.56 | 1202.35 | 1020.93 | 891.1 |
| Profit After Tax | 46.2 | 149.43 | 90.5 | 84.93 |
| Net Worth | 607.02 | 606.34 | 480.41 | 408.52 |
| Reserve & Surplus | 545.86 | 545.18 | 419.25 | 347.36 |
| Total Borrowings | 106.65 | 62.7 | 134.14 | 2.33 |
Financials Performance
Performance Indicators
EPS Pre
Earnings per share before the IPO.
P/E Pre
IPO Offer Price ÷ EPS Pre.
EPS Post
Expected earnings per share after the IPO..
P/E (Post Issue)
IPO Offer Price ÷ EPS Post.
Corona Remedies Limited KPI Information
| Particular | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| ROE % | 27.5 | 20.36 | 23.29 |
| ROCE % | 41.32 | 31.19 | 28.36 |
| Debt / Equity | 0.1 | 0.28 | 0.01 |
| RoNW % | 24.65 | 18.84 | 20.79 |
| Pat Margin % | 12.49 | 8.92 | 9.61 |
Peers Comparison
| Company | Face Value | PE Ratio | EPS Basic | EPS Diluted | RoNW | Net Assets |
|---|---|---|---|---|---|---|
| CORONA Remedies Ltd | 10 | 0.00 | 24.43 | 24.43 | 24.65 | 99.14 |
| Abbott India Ltd | 10 | 45.17 | 665.62 | 665.62 | 33.41 | 1992.14 |
| Alkem Laboratories Ltd | 2 | 31.39 | 181.11 | 181.11 | 18.07 | 1002.37 |
| Eris Lifesciences Ltd | 1 | 61.81 | 25.85 | 25.81 | 12.21 | 209.73 |
| GlaxoSmithKline Pharmaceuticals Ltd | 10 | 46.87 | 54.76 | 54.76 | 47.54 | 115.19 |
About Corona Remedies Limited
Corona Remedies Limited, incorporated in August 2004, is a fast-growing pharmaceutical formulation company focused on the Indian market. The company develops, manufactures, and markets a wide range of branded products across women’s healthcare, cardio-diabeto, pain management, urology, and other key therapeutic segments, including vitamins/minerals/nutrition, gastrointestinal, and respiratory care.
As of December 2024, Corona’s portfolio comprised 67 brands, which expanded to 71 brands by MAT June 2025. Of these, 27 are “engine brands”, contributing over 72% of domestic sales. The company has built strong positions across chronic and sub-chronic therapies, which accounted for 70.10% of domestic revenues and grew at a notable 20.48% CAGR over the period.
Corona has established a strong commercial footprint through a pan-India marketing and distribution network, supported by 2,598–2,671 medical representatives across 22 states, enabling deep engagement with healthcare professionals and robust penetration across its targeted therapy areas. The company ranks 29th in the Indian Pharmaceutical Market (IPM) and 17th in covered markets.
The company operates two manufacturing facilities—one in Gujarat and another in Himachal Pradesh—backed by a strong focus on quality and current Good Manufacturing Practices (cGMP). As of December 31, 2024, Corona employed 88 R&D professionals, underpinning its commitment to developing differentiated pharmaceutical products and strengthening its innovation pipeline. Strategic acquisitions, such as Myoril from Sanofi, have further expanded its specialty portfolio.
Competitive Strengths
- One of the fastest-growing companies among the top 30 IPM players, with a 13.58% CAGR in domestic sales from MAT June 2024 to MAT June 2025, outpacing the IPM growth of 7.90%.
- Proven ability to build a broad, diversified brand portfolio, strengthened by high-performing “engine brands.”
- Extensive pan-India sales infrastructure and a marketing strategy focused on the high-potential “middle of the pyramid” segment.
- Quality-driven manufacturing capabilities and strong R&D focus enabling a pipeline of differentiated formulations.
- Experienced and entrepreneurial leadership team supported by marquee institutional investors.
Corona Remedies IPO Promoters
- Dr. Kirtikumar Laxmidas Mehta
- Niravkumar Kirtikumar Mehta
- Ankur Kirtikumar Mehta
Promoters Holding
Holding Pre Issue
72.50%
Holding Post Issue
0.00%
Corona Remedies IPO Objective
Corona Remedies Limited Address / Contact Details
Corona Remedies Limited
CORONA House, C – Mondeal Business Park
Near Gurudwara S. G. Highway
Thaltej Ahmedabad, Gujarat, 380059
Phone: +91 79 4023 3000
Email: complianceofficer@coronaremedies.com
Website: https://www.coronaremedies.com/
IPO Snapshot
Corona Remedies IPO Lot Size
The Corona Remedies IPO has a lot size of 14 shares. Retail investors require a minimum investment of ₹14,868 by applying for 1 lot (14 shares). The maximum application allowed for the retail category is 13 lots (182 shares), requiring an investment of ₹1,93,284.
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 14 | 14,868.00 |
| Retail (Max) | 13 | 182 | 193,284.00 |
| S-HNI (Min) | 14 | 196 | 208,152.00 |
| S-HNI (Max) | 67 | 938 | 996,156.00 |
| B-HNI (Min) | 68 | 952 | 1,011,024.00 |
Issue Reservation
- QIB — 28.19%
- NII — 21.14%
- RII — 49.33%
- EMP — 1.34%
Book Running Lead Managers
- IIFL Capital Services Limited
- JM Financial Limited
- Kotak Mahindra Capital Company Limited
IPO Documents & Links
Explore More IPOs
Currently Open
Coming Up Next
Disclaimer: This data is for informational purposes only and does not constitute investment advice.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
What is the Corona Remedies IPO?
Corona Remedies IPO is a Book-building IPO with a total issue size of ₹655.37 crore. The Corona Remedies IPO price band is ₹1008 to 1062 per share. The Corona Remedies IPO subscription opens on Mon, Dec 8, 2025, and closes on Wed, Dec 10, 2025. The Corona Remedies IPO will be listed on the BSE,NSE. Bigshare Services Pvt Ltd is the registrar for the Corona Remedies IPO.
When will the Corona Remedies IPO open for subscription?
The Corona Remedies IPO opens on Mon, Dec 8, 2025 and closes on Wed, Dec 10, 2025
What is Corona Remedies IPO Price Band?
Corona Remedies IPO Price Band is ₹1008 to 1062 per share.
What is Corona Remedies IPO Lot Size?
Corona Remedies IPO lot size is 14 shares, Retail investors need a minimum investment of ₹14868 based on the upper price band
What is the minimum investment for Corona Remedies IPO?
The minimum investment for Corona Remedies IPO is ₹14868, based on one lot of 14 shares at the upper price band of ₹1062 per share.
How to apply for Corona Remedies IPO?
Investors can apply for the Corona Remedies IPO through the ASBA (Application Supported by Blocked Amount) facility offered by their bank or through UPI using a SEBI-registered broker or trading app. Select the desired lot size, enter your bid within the price band, and submit the application before Wed, Dec 10, 2025. The application amount remains blocked until the Corona Remedies IPO allotment is finalized.
What is Corona Remedies IPO Issue Size?
Corona Remedies IPO issue size is ₹655.37 crores.
What is the Corona Remedies IPO Allotment Date?
Corona Remedies IPO allotment date is Thu, Dec 11, 2025.
Who is the Corona Remedies IPO Registrar?
The registrar for Corona Remedies IPO is Bigshare Services Pvt Ltd. Investors can go to Bigshare Services Pvt Ltd website to check Corona Remedies IPO allotment status, refund processing, and other IPO-related information.
What is the Corona Remedies IPO GMP?
The Corona Remedies IPO GMP (Grey Market Premium) is ₹342 as of Mon, Dec 15, 2025. Based on the upper price band of ₹1062 per share, the estimated Corona Remedies IPO listing price is ₹1404, indicating a potential listing gain of approximately 32.20% over the issue price.
Who is the Corona Remedies IPO Lead Manager?
The book-running lead managers (BRLMs) for the Corona Remedies IPO are IIFL Capital Services Limited, JM Financial Limited, and Kotak Mahindra Capital Company Limited. The lead managers are responsible for managing the IPO process, including issue structuring, regulatory compliance, marketing the public issue, coordinating with investors, and ensuring a smooth listing process. For complete details, investors should refer to the Corona Remedies IPO Red Herring Prospectus (RHP).